|
1
|
Maingon P and Huguet F: Rectal Cancer: The
Radiation Oncologist: The Great Watchmaker. Semin Radiat Oncol.
26:173–175. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cienfuegos JA, Rotellar F, Baixauli J,
Beorlegui C, Sola JJ, Arbea L, Pastor C, Arredondo J and
Hernández-Lizoáin JL: Impact of perineural and lymphovascular
invasion on oncological outcomes in rectal cancer treated with
neoadjuvant chemoradiotherapy and surgery. Ann Surg Oncol.
22:916–923. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Suárez-Villanueva S, Ayala-Madrigal ML,
Peregrina-Sandoval J, Macías-Gómez N, Ramírez-Ramírez R,
Muñiz-Mendoza R, Moreno-Ortiz JM, Centeno-Flores M,
Maciel-Gutiérrez V, Cabrales E, et al: RUNX3 gene polymorphisms and
haplotypes in Mexican patients with colorectal cancer. Genet Mol
Res. 14:15505–15510. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Almaraz RT, Tian Y, Bhattarcharya R, Tan
E, Chen SH, Dallas MR, Chen L, Zhang Z, Zhang H, Konstantopoulos K,
et al: Metabolic flux increases glycoprotein sialylation:
implications for cell adhesion and cancer metastasis. Mol Cell
Proteomics. 11:M112.017558. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Su SC, Hsieh MJ, Yang WE, Chung WH, Reiter
RJ and Yang SF: Cancer metastasis: Mechanisms of inhibition by
melatonin. J Pineal Res. 62:622017. View Article : Google Scholar
|
|
7
|
Slattery ML, Lundgreen A, Herrick JS, Caan
BJ, Potter JD and Wolff RK: Associations between genetic variation
in RUNX1, RUNX2, RUNX3, MAPK1 and eIF4E and riskof colon and rectal
cancer: Additional support for a TGF-β-signaling pathway.
Carcinogenesis. 32:318–326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Barghout SH, Zepeda N, Vincent K, Azad AK,
Xu Z, Yang C, Steed H, Postovit LM and Fu Y: RUNX3 contributes to
carboplatin resistance in epithelial ovarian cancer cells. Gynecol
Oncol. 138:647–655. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kang KA, Zhang R, Kim GY, Bae SC and Hyun
JW: Epigenetic changes induced by oxidative stress in colorectal
cancer cells: Methylation of tumor suppressor RUNX3. Tumour Biol.
33:403–412. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen F, Liu X, Bai J, Pei D and Zheng J:
The emerging role of RUNX3 in cancer metastasis (Review). Oncol
Rep. 35:1227–1236. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moon JW, Lee SK, Lee JO, Kim JH, Kim N,
Kim J, Kim HS and Park SH: Demethylation of RUNX3 by vincristine in
colorectal adenocarcinoma cells. Anticancer Res. 34:133–140.
2014.PubMed/NCBI
|
|
12
|
Nishina S, Shiraha H, Nakanishi Y, Tanaka
S, Matsubara M, Takaoka N, Uemura M, Horiguchi S, Kataoka J,
Iwamuro M, et al: Restored expression of the tumor suppressor gene
RUNX3 reduces cancer stem cells in hepatocellular carcinoma by
suppressing Jagged1-Notch signaling. Oncol Rep. 26:523–531.
2011.PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2 (-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Slattery ML, Lundgreen A, Herrick JS,
Wolff RK and Caan BJ: Genetic variation in the transforming growth
factor-β signaling pathway and survival after diagnosis with colon
and rectal cancer. Cancer. 117:4175–4183. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nie K, Shi L, Chen Q, Hu X, Jabbour SK,
Yue N, Niu T and Sun X: Rectal cancer: Assessment of neoadjuvant
chemoradiation outcome based on radiomics of multiparametric MRI.
Clin Cancer Res. 22:5256–5264. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Acuna SA, Chesney TR and Baxter NN:
Pathologic outcomes of laparoscopic vs open mesorectal excision for
rectal cancer. JAMA Surg. 152:986–987. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim YS, Chae YK, Choi YS, Min JH, Ahn SW,
Yoon JW, Lee SE and Lee YK: A comparative study of emergence
agitation between sevoflurane and propofol anesthesia in adults
after closed reduction of nasal bone fracture. Korean J
Anesthesiol. 63:48–53. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Slattery ML and Lundgreen A: The influence
of the CHIEF pathway on colorectal cancer-specific mortality. PLoS
One. 9:e1161692014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim BR, Kang MH, Kim JL, Na YJ, Park SH,
Lee SI, Kang S, Joung SY, Lee SY, Lee DH, et al: RUNX3 inhibits the
metastasis and angiogenesis of colorectal cancer. Oncol Rep.
36:2601–2608. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang M, Li C, Yu B, Su L, Li J, Ju J, Yu
Y, Gu Q, Zhu Z and Liu B: Overexpressed miR-301a promotes cell
proliferation and invasion by targeting RUNX3 in gastric cancer. J
Gastroenterol. 48:1023–1033. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bauer O, Hantisteanu S, Lotem J and Groner
Y: Carcinogen-induced skin tumor development requires leukocytic
expression of the transcription factor Runx3. Cancer Prev Res
(Phila). 7:913–926. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Milford TA, Su RJ, Francis OL, Baez I,
Martinez SR, Coats JS, Weldon AJ, Calderon MN, Nwosu MC, Botimer
AR, et al: TSLP or IL-7 provide an IL-7Rα signal that is critical
for human B lymphopoiesis. Eur J Immunol. 46:2155–2161. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee CW, Chuang LS, Kimura S, Lai SK, Ong
CW, Yan B, Salto-Tellez M, Choolani M and Ito Y: RUNX3 functions as
an oncogene in ovarian cancer. Gynecol Oncol. 122:410–417. 2011.
View Article : Google Scholar : PubMed/NCBI
|
